Rocket Pharmaceuticals (RCKT) Capital Expenditures (2015 - 2026)

Rocket Pharmaceuticals has reported Capital Expenditures for 12 years, with the latest figure at $93000.0 in Q1 2026.

• Quarterly Capital Expenditures rose 82.35% year-over-year to $93000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $482000.0 (down 87.57% YoY) and the FY2025 annual result came in at $440000.0, down 92.49% from the prior year.
• Capital Expenditures rose to $93000.0 in Q1 2026 per RCKT's latest filing, from $80000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $14.8 million in Q4 2023 and troughed at -$3.7 million in Q3 2024.
• A 5-year average of $1.5 million and a median of $405000.0 in 2023 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures surged 552.94% in 2023, then plunged 1013.58% in 2024.
• Over 5 years, Capital Expenditures stood at -$3.3 million in 2022, then soared by 552.94% to $14.8 million in 2023, then slumped by 62.1% to $5.6 million in 2024, then slumped by 98.57% to $80000.0 in 2025, then advanced by 16.25% to $93000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $93000.0, $80000.0, and $360000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.